Bridging The Gap: Cyclenium Pharma

Emerging Company Profile: Cyclenium Pharma spoke with Scrip about macrocyclic drug discovery, which covers the molecular space between traditional small molecules and large bio-molecules, to capture the pharmacological properties of larger peptides/proteins in metabolically stable small molecules and proven in a broad range of target classes.

Emerging Company Profile Regular column feature image Version 2

Cyclenium Pharma Inc., founded five years ago by Helmut Thomas and Mark Petersen in Quebec, Canada, is a small molecule macrocycle company with a drug discovery technology, Customized Macrocycles for Recognition of Topologies (CMRT), and a screening library, QUEST, for the discovery and development of drugs for areas of unmet medical need.

Macrocyclic drug discovery fills the molecular space between traditional small molecules and large bio-molecules. Although Cyclenium Pharma has been incorporated for just five years, its founders and team came from...

Tranzyme was one of the pioneers in the generation and use of small molecule macrocycles for drug discovery. Having lost the patents to previous work, Thomas, previously senior vice president...

More from Anti-infective

More from Therapy Areas

Gilead Ready To Go After Hepatitis D Again

 
• By 

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By 

The UK major's asthma drug gets a key expanded approval.